Pedersen I B, Knudsen N, Perrild H, Ovesen L, Laurberg P
Department of Endocrinology and Medicine, Aalborg Hospital, Aalborg, Denmark.
Clin Endocrinol (Oxf). 2001 Sep;55(3):381-90. doi: 10.1046/j.1365-2265.2001.01347.x.
Graves' disease is characterized by stimulating autoantibodies to the TSH-receptor (TRAb). The aim of this study was to compare the performance of a new TRAb assay based on competitive binding to recombinant human TSH-receptors (H-TRAb) with an assay employing purified porcine TSH-receptors (P-TRAb). Furthermore, to evaluate the applicability of the H-TRAb assay to discriminate between patients with hyperthyroidism due to Graves' disease (GD) and multinodular toxic goitre (MNTG).
H-TRAb and P-TRAb were measured in patients with newly diagnosed hyperthyroidism due to GD (n = 106) and MNTG (n = 94). For comparison, TRAb was measured in patients with primary autoimmune hypothyroidism, euthyroid subjects with an enlarged thyroid gland by ultrasound, and healthy controls (n = 100 for each group). Patients were consecutively included from a population survey.
If the cut-off values recommended by the manufacturer for TSH-receptor antibody positivity were used for evaluation, the sensitivity of the H-TRAb assay vs. the P-TRAb assay in diagnosing GD was: 95.3/67.9% (P < 0.001). Specificity was (H/P-TRAb): 99/99%. The sensitivity of P-TRAb was increased if the upper 97.5% limit of measurements in controls was used as cut-off (H-TRAb vs. P-TRAb: 95.3/80.2%, P < 0.001). Specificity (H/P-TRAb): 98/98%. The difference between assay performance may partly be due to a better technical performance of the H-TRAb assay with more reliable results in the low range of measurements. However, even in GD patients with clearly measurable TRAb, 25% had a P-TRAb < 50% of the value expected from the H-TRAb measurement. This suggests that a subgroup of patients produce TRAb with a higher affinity for the human than the porcine TSH receptor. A relatively high proportion of patients with MNTG were TRAb positive (H-TRAb/P-TRAb: 17/9%). Characteristics of H-TRAb positive and negative MNTG patients were compared. There was no difference between size of thyroid gland and number of nodules by ultrasonography. H-TRAb positive patients had significantly higher serum T4 and T3 and a greater number were TPO-Ab positive.
H-TRAb diagnosed Graves' disease with a high sensitivity and specificity than P-TRAb. The high occurrence of TRAb in multinodular toxic goitre might in part reflect an overlap between Graves' disease and multinodular toxic goitre in some patients.
格雷夫斯病的特征是存在刺激促甲状腺激素受体(TRAb)的自身抗体。本研究的目的是比较一种基于与重组人促甲状腺激素受体竞争性结合的新型TRAb检测方法(H - TRAb)与采用纯化猪促甲状腺激素受体的检测方法(P - TRAb)的性能。此外,评估H - TRAb检测方法在鉴别格雷夫斯病(GD)所致甲状腺功能亢进患者和多结节毒性甲状腺肿(MNTG)患者方面的适用性。
对因GD(n = 106)和MNTG(n = 94)导致的新诊断甲状腺功能亢进患者测量H - TRAb和P - TRAb。作为对照,对原发性自身免疫性甲状腺功能减退患者、超声检查甲状腺肿大的甲状腺功能正常受试者以及健康对照者(每组n = 100)测量TRAb。患者是从一项人群调查中连续纳入的。
如果使用制造商推荐的促甲状腺激素受体抗体阳性临界值进行评估,H - TRAb检测方法与P - TRAb检测方法在诊断GD时的敏感性分别为:95.3%/67.9%(P < 0.001)。特异性为(H/P - TRAb):99%/99%。如果将对照组测量值的上97.5%限用作临界值,则P - TRAb的敏感性会提高(H - TRAb与P - TRAb:95.3%/80.2%,P < 0.001)。特异性(H/P - TRAb):98%/98%。检测性能的差异可能部分归因于H - TRAb检测方法技术性能更好且在低测量范围内结果更可靠。然而,即使在TRAb可明确测量的GD患者中,25%的患者P - TRAb值低于H - TRAb测量预期值的50%。这表明有一部分患者产生的TRAb与人促甲状腺激素受体的亲和力高于与猪促甲状腺激素受体的亲和力。相当比例的MNTG患者TRAb呈阳性(H - TRAb/P - TRAb:17%/9%)。对H - TRAb阳性和阴性的MNTG患者的特征进行了比较。超声检查显示甲状腺大小和结节数量无差异。H - TRAb阳性患者的血清T4和T3显著更高,且更多患者TPO - Ab呈阳性。
与P - TRAb相比,H - TRAb诊断格雷夫斯病具有更高的敏感性和特异性。多结节毒性甲状腺肿中TRAb的高发生率可能部分反映了某些患者中格雷夫斯病和多结节毒性甲状腺肿之间的重叠。